Guidelines for the treatment of psoriatic arthritis with biologics

• Deborah Symmons Professor of Rheumatology and Musculoskeletal Epidemiology, The University of
Manchester served on the committee, advised on the section on safety and participated in the
preparation and final approval of the manuscript. DS is a Principal Investigator of the BSR Biologics
Register –RA which is funded by the British Society for Rheumatology who in turn receives funding
from Abbott, Merck, Pfizer, Roche and UCB to support the register.
• William Tillett Research Fellow, Royal National Hospital for Rheumatic Diseases, Bath UK, served on
the committee, reviewed relevant literature, undertook the guideline audit and participated in
preparation and final approval of the manuscript. WT as no conflicts of interest to declare.
• Nicola Waldron Psoriatic Arthritis Nurse Specialist, Royal National Hospital for Rheumatic Diseases,
Bath UK. served on the committee, and participated in preparation and final approval of the
manuscript. NW has received honoraria from Abbott.
Acknowledgments
To the BSR audit and guidelines working group and in particular previous Chair Dr Josh Dixey and present
Chair Dr Jo Ledingham and to the BSR office
To external reviewers Professor Oliver Fitzgerald, Professor Ade Adebayo, Professor David Burden and Dr
Richard Warren
19